06.24.15
Spinal surgical device and instrument maker Amendia Inc. has purchased certain assets of SpineSelect LLC of Tupelo, Miss., a spine company focused on providing minimally invasive systems, implants and instruments. With this acquisition, Amendia broadens its portfolio to include a minimally invasive transforaminal lumbar interbody fusion (MITLIF) system. Through this transaction the Marietta. Ga.-based company gains 20 patents covering SpineSelect’s core products and other spinal technologies.
“The addition of SpineSelect’s MITLIF system allows Amendia to offer another superior solution for both patients and surgeons,” said Jeff Smith, CEO of Amendia. “We look forward to building relationships with SpineSelect’s current customers and distribution groups, while expanding our product portfolio with novel technologies.”
SpineSelect’s MITLIF system is comprised of two primary product families: the Marquise MIS channel system and the Turbo MIS TLIF system. The patented Turbo MIS interbody devices, which hold U.S. Food and Drug Administration clearance, were designed to overcome many of the deficiencies of commodity devices, including stability and rollover, insertion safety, poor visualization, subsidence and kyphosis, and suboptimal fusion rates. The Marquise MIS channel system’s patented design is meant to satisfy the conflicting goals of limiting muscle damage while also providing the surgeon adequate working access for complex surgical procedures.
“The team at SpineSelect has worked hard to develop truly differentiated technology, covered by 20 patents, that helps surgeons perform less invasive lumbar fusion procedures and achieve better patient outcomes,” said John Eckman, president of SpineSelect. “We are thrilled that Amendia shares the same commitment to delivering innovative, outcomes-driven technology. I am amazed by the amount of innovation occurring at Amendia, and we look forward to joining this dynamic and emerging leader in the spine industry.”
“The addition of SpineSelect’s MITLIF system allows Amendia to offer another superior solution for both patients and surgeons,” said Jeff Smith, CEO of Amendia. “We look forward to building relationships with SpineSelect’s current customers and distribution groups, while expanding our product portfolio with novel technologies.”
SpineSelect’s MITLIF system is comprised of two primary product families: the Marquise MIS channel system and the Turbo MIS TLIF system. The patented Turbo MIS interbody devices, which hold U.S. Food and Drug Administration clearance, were designed to overcome many of the deficiencies of commodity devices, including stability and rollover, insertion safety, poor visualization, subsidence and kyphosis, and suboptimal fusion rates. The Marquise MIS channel system’s patented design is meant to satisfy the conflicting goals of limiting muscle damage while also providing the surgeon adequate working access for complex surgical procedures.
“The team at SpineSelect has worked hard to develop truly differentiated technology, covered by 20 patents, that helps surgeons perform less invasive lumbar fusion procedures and achieve better patient outcomes,” said John Eckman, president of SpineSelect. “We are thrilled that Amendia shares the same commitment to delivering innovative, outcomes-driven technology. I am amazed by the amount of innovation occurring at Amendia, and we look forward to joining this dynamic and emerging leader in the spine industry.”